読み込み中
NASDAQHealthcareBiotechnology
最新データ
$24.92
+$0.30 · +1.22%
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
前日終値
$24.92
+$0.30 · +1.22%
日中の時刻はETです。市場データは遅延する場合があります。
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
日中レンジ
現在 $24.92
52週レンジ
現在 $24.92
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
40
割高
センチメント
46
まちまち
リスク
53
やや高いリスク
モメンタム
58
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
日中レンジ
現在 $24.92
52週レンジ
現在 $24.92
| 指標（USD） | 2025年度 |
|---|---|
| 売上原価 | 61.2万 USD |
| 粗利益 | −61.2万 USD |
| 研究開発 | 2864万 USD |
| 販売・一般管理 | 1219.7万 USD |
| 営業費用 | 4083.7万 USD |
| 受取利息 | 310.6万 USD |
| 減価償却費と償却費 | 61.2万 USD |
| 営業利益 | −4144.9万 USD |
| 純利益 | −3986.9万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$38.00
上昇余地（52.49%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI827.51万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM613.37万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF295.59万0.00%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO166.09万0.01%180億 USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO145.68万0.01%139.17億 USD0.24%$356.78+0.94%
ALPS Medical Breakthroughs ETFSBIO105.83万0.55%1.91億 USD0.50%$55.04+2.03%
Avantis Emerging Markets Equity ETFAVEM99.63万—284.09億 USD0.33%$94.11+0.93%
Schwab U.S. Small-Cap ETFSCHA87.35万0.00%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOALPS Medical Breakthroughs ETFSBIOAvantis Emerging Markets Equity ETFAVEMSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
